Metastatic Breast Cancer

27 competing products in clinical development for Metastatic Breast Cancer.

Pipeline by Phase

Pre-clinical2

Phase 12

Phase 1/27

Phase 212

Phase 34

All Products (27)

Product	Company	Stage	Status	Hype
pertuzumab + Trastuzumab + Capecitabine + Paclitaxel + Vinorelbine + Docetaxel + Exemestane + Letrozole + Anastrozole + Fulvestrant + Ribociclib + nab-Paclitaxel + eribulin + leuprorelin + goserelin	Eisai	Phase 3	Active	44
Induction therapy	Chugai Pharmaceutical	Phase 2	Recruiting	42
U3-1402	Daiichi Sankyo	Phase 2	Recruiting	42
Eribulin + Sacituzumab govitecan + Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	Recruiting	42
Enzalutamide + Mifepristone + TPC	Astellas Pharma	Phase 2	Recruiting	42
CT-P6 + Herceptin + Paclitaxel	Celltrion	Phase 3	Completed	40
Eribulin Mesylate + Capecitabine	Eisai	Phase 3	Completed	40
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)	Zydus Lifesciences	Phase 3	Completed	40
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	Active	39
Trastuzumab deruxtecan + Durvalumab + Paclitaxel + Pertuzumab + Tucatinib	Daiichi Sankyo	Phase 1/2	Active	36
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelin	Chugai Pharmaceutical	Phase 2	Completed	35
bevacizumab + Paclitaxel	Chugai Pharmaceutical	Phase 2	Completed	35
U3-1402	Daiichi Sankyo	Phase 2	Completed	35
Paclitaxel + Eribulin + Gemcitabine	Eisai	Phase 2	Completed	35
Eribulin + Trastuzumab	Eisai	Phase 2	Completed	35
Trastuzumab deruxtecan + Durvalumab + Paclitaxel + Capivasertib + Anastrozole + Fulvestrant + Capecitabine	Daiichi Sankyo	Phase 1	Active	33
CT-P6 + Herceptin + Paclitaxel	Celltrion	Phase 1/2	Completed	32
Patritumab Deruxtecan	Daiichi Sankyo	Phase 1/2	Completed	32
Eribulin mesylate + Capecitabine	Eisai	Phase 1/2	Completed	32
Proxalutamide	Sun Pharmaceutical	Phase 1	Completed	29
Nivolumab	Eisai	Phase 1/2	UNKNOWN	28
E7070	Eisai	Phase 2	Terminated	27
Eribulin	Eisai	Phase 2	Withdrawn	27
Eribulin Mesylate	Eisai	Pre-clinical	Completed	26
U3-1287 + Trastuzumab + Paclitaxel + U3-1287 + Trastuzumab + Paclitaxel + Placebo	Daiichi Sankyo	Phase 1/2	Terminated	24
Eribulin mesylate + Eribulin mesylate + Eribulin mesylate	Eisai	Phase 1/2	Terminated	24
Eribulin Mesylate	Eisai	Pre-clinical	UNKNOWN	22